Literature DB >> 10556677

Anticonvulsant activity of a metabotropic glutamate receptor 8 preferential agonist, (R,S)-4-phosphonophenylglycine.

A G Chapman1, K Nanan, P Yip, B S Meldrum.   

Abstract

Agonists at group III glutamate metabotropic receptors, such as L-serine-O-phosphate, have pro- and anti-convulsant activities in rodent models. We have used intracerebroventricular administration to test a novel group III agonist, (R,S)-4-phosphonophenylglycine (PPG), that is preferential for mglu(8), against sound-induced seizures in DBA/2 mice. Tonic and clonic seizures are abolished at 15 min (ED(50s) 0.14 [0.04-0.4] nmol, and 3.4 [2.1-5.6] nmol, respectively). The protection against tonic and clonic seizures by 20 nmol PPG is complete for 4 h, diminished by 6 h, and absent by 10 h. In contrast, L-Serine-O-phosphate gives only partial protection against sound-induced clonic seizures for 15-30 min (ED(50) 79 [45-139] nmol) in DBA/2 mice. In genetically epilepsy prone rats sound-induced seizures were blocked 5-60 min after the bilateral administration of PPG, 5-10 nmol, into the inferior colliculus. These data suggest that the mglu(8) receptor is a potential target for novel antiepileptic drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10556677     DOI: 10.1016/s0014-2999(99)00615-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

Review 1.  Therapeutic devices for epilepsy.

Authors:  Robert S Fisher
Journal:  Ann Neurol       Date:  2012-02       Impact factor: 10.422

Review 2.  Group III metabotropic glutamate receptors: pharmacology, physiology and therapeutic potential.

Authors:  Marion S Mercier; David Lodge
Journal:  Neurochem Res       Date:  2014-08-22       Impact factor: 3.996

3.  Increased seizure susceptibility in mice lacking metabotropic glutamate receptor 7.

Authors:  G Sansig; T J Bushell; V R Clarke; A Rozov; N Burnashev; C Portet; F Gasparini; M Schmutz; K Klebs; R Shigemoto; P J Flor; R Kuhn; T Knoepfel; M Schroeder; D R Hampson; V J Collett; C Zhang; R M Duvoisin; G L Collingridge; H van Der Putten
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

4.  Agonists and antagonists of metabotropic glutamate receptors: anticonvulsants and antiepileptogenic agents?

Authors:  Feng Ru Tang
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

5.  Phenylglycine derivatives as antagonists of group III metabotropic glutamate receptors expressed on neonatal rat primary afferent terminals.

Authors:  Jacqueline C Miller; Patrick A Howson; Stuart J Conway; Richard V Williams; Barry P Clark; David E Jane
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

6.  Group III mGlu receptor agonist, ACPT-I, exerts potential neuroprotective effects in vitro and in vivo.

Authors:  Helena Domin; Krystyna Gołembiowska; Danuta Jantas; Katarzyna Kamińska; Barbara Zięba; Maria Smiałowska
Journal:  Neurotox Res       Date:  2014-01-09       Impact factor: 3.911

7.  Hippocampus RNA Sequencing of Pentylenetetrazole-Kindled Rats and Upon Treatment of Novel Chemical Q808.

Authors:  Xiang Li; Qing Wang; Dian-Wen Zhang; Di Wu; Si-Wei Zhang; Zheng-Ren Wei; Xia Chen; Wei Li
Journal:  Front Pharmacol       Date:  2022-03-08       Impact factor: 5.810

8.  Therapeutic potential of metabotropic glutamate receptor modulators.

Authors:  N Hovelsø; F Sotty; L P Montezinho; P S Pinheiro; K F Herrik; A Mørk
Journal:  Curr Neuropharmacol       Date:  2012-03       Impact factor: 7.363

Review 9.  Metabotropic Glutamate Receptors and Interacting Proteins in Epileptogenesis.

Authors:  Feng Qian; Feng-Ru Tang
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.